The long term goals of this work include the development of an understanding of the role(s) of the ser/thr protein kinase Rsk family in signal transduction within the mitogenactivated protein kinase (MAPK) pathway, and the identification of new classes of potential antitumor agents. The immediate objectives include -chemical synthesis of analogues of a group of kaempferol glycosides shown to mediate hightly selective inhibition of Rsk2 -synthesis of analogues of a second class of inhibitors identified from the NCI repository by in silico screening -identification of additional naturally occurring inhibitors of p90 Rsk that have different types of chemical structures and properties
|Effective start/end date||8/6/08 → 1/31/10|
- HHS-NIH: National Cancer Institute (NCI): $262,229.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.